Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only…
Mipsagargin (G-202), a new prodrug developed by GenSpera, has a unique mechanism of action that allows it to kill cancer cells without damaging surrounding tissues. Derived from thapsigargin,…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Engineers have developed 3D-printable miniature "fish" that may be capable of propelling themselves through blood vessels and delivering drugs to specific cells.
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
